Journal article
The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice
Surgical pathology clinics, Vol.15(3), pp.491-502
09/01/2022
DOI: 10.1016/j.path.2022.05.004
PMID: 36049831
Abstract
Identification of deleterious germline mutations in pancreatic ductal adenocarcinoma (PDAC) patients can have therapeutic implications for the patients and result in cascade testing and prevention in their relatives. Universal testing for germline mutations is now considered standard of care in patients with PDAC, regardless of family history, personal history, or age. Here, we highlight the commonly identified germline mutations in PDAC patients as well as the impact of multigene panel testing. We further discuss therapeutic implications of germline testing on the index cases, and the impact of cascade testing on cancer early detection and prevention in relatives.
Details
- Title: Subtitle
- The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice
- Creators
- Chirayu Mohindroo - The University of Texas MD Anderson Cancer CenterAna De Jesus-Acosta - Johns Hopkins UniversityMatthew B. Yurgelun - Dana-Farber Cancer InstituteAnirban Maitra - The University of Texas MD Anderson Cancer CenterMaureen Mork - The University of Texas MD Anderson Cancer CenterFlorencia McAllister - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Surgical pathology clinics, Vol.15(3), pp.491-502
- DOI
- 10.1016/j.path.2022.05.004
- PMID
- 36049831
- ISSN
- 1875-9181
- eISSN
- 1875-9157
- Publisher
- Elsevier Inc
- Number of pages
- 12
- Language
- English
- Date published
- 09/01/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985178656202771
Metrics
1 Record Views